XML 73 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
License and Research Agreements - Additional Information (Details)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Nov. 07, 2017
USD ($)
Oct. 31, 2018
USD ($)
Jun. 30, 2018
USD ($)
Oct. 31, 2015
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Dec. 31, 2018
USD ($)
DiseaseIndication
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Collaboration and license revenue           $ 16,261,000 $ 11,763,000 $ 12,794,000 $ 10,677,000 $ 2,414,000 $ 198,000 $ 51,495,000 $ 2,612,000 $ 133,000
Research and development                       293,998,000 231,644,000 183,204,000
Contract asset           2,979,000           2,979,000    
Dimension                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Collaboration and license revenue         $ 2,100,000                  
Business acquisition date Nov. 07, 2017                          
Business combination recognized intangible assets $ 129,000,000                          
Research and development                       $ 12,300,000 1,000,000  
Amortization completion year                       2019    
Dimension | Contract Asset                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Business combination recognized intangible assets 13,500,000                          
Bayer HealthCare LLC                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Collaboration and license revenue                       $ 23,500,000 2,100,000  
Contract liability $ 2,500,000       5,400,000         5,400,000     5,400,000  
Contract asset           3,000,000           3,000,000    
Product Sales                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Collaboration and license revenue                       9,802,000 476,000 133,000
Kyowa Hakko Kirin Collaboration                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Reduction in research and development expenses                       32,240,000 31,165,000 $ 25,356,000
Kyowa Hakko Kirin Collaboration | License Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Collaboration and license revenue                       15,300,000    
Kyowa Hakko Kirin Collaboration | License Agreement | Prepaid and Other Current Assets                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
License agreement other receivables           11,100,000           11,100,000    
Kyowa Hakko Kirin Collaboration | License Agreement | Product Sales                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Collaboration and license revenue                       600,000    
Kyowa Hakko Kirin Collaboration | License Agreement | Profit Share Revenue                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
License agreement accounts receivable         9,000 11,200,000       9,000   $ 11,200,000 9,000  
Kyowa Hakko Kirin Collaboration | License Agreement | Commercial and Development Activity Reimbursements                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
License agreement other receivables         10,300,000         10,300,000     10,300,000  
Kyowa Hakko Kirin Collaboration | Profit Share Territory | License Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Remaining profit or loss share percentage on commercializing products                       50.00%    
Tiered double-digit revenue share percentage entitled to receive                       20.00%    
Kyowa Hakko Kirin Collaboration | European Territory | License Agreement | Maximum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Percentage of royalty on net sales entitled to receive                       10.00%    
Saint Louis University License Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Milestone payments paid                       $ 100,000    
Baylor Research Institute License Agreement | Development Milestones                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Future contingent milestone payments           5,300,000           5,300,000    
Baylor Research Institute License Agreement | Sales Milestones                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Future contingent milestone payments           7,500,000           $ 7,500,000    
Option and License Agreement | REGENXBIO, Inc.                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Option and license agreement description                       The Company also has an option and license agreement with REGENX under which the Company has an exclusive, sublicensable, worldwide license to make, have made, use, import, sell, and offer for sale licensed products with respect to three disease indications, subject to certain exclusions and has an option for another disease indication. In October 2018, the Company exercised its remaining option with REGENX for the additional disease indication and paid a $1.0 million fee for the exercise of the option.    
Number of disease indications for exclusive license | DiseaseIndication                       3    
Fee paid for exercise of option   $ 1,000,000                        
Annual maintenance fee for each option exercised                       $ 100,000    
Option and License Agreement | Maximum | REGENXBIO, Inc.                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Future contingent milestone payments           9,000,000           9,000,000    
Research, Develop and Commercialize AAV Gene Therapy Products | Bayer HealthCare LLC                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Milestone payments received                       15,000,000    
Research, Develop and Commercialize AAV Gene Therapy Products | Maximum | Bayer HealthCare LLC                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Future contingent milestone payments           232,000,000           232,000,000    
Research Collaboration and License Agreement Development Milestones | Maximum | University of Pennsylvania School of Medicine (Penn)                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Future contingent milestone payments           5,000,000           5,000,000    
Research Collaboration and License Agreement Commercial Milestones | Maximum | University of Pennsylvania School of Medicine (Penn)                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Future contingent milestone payments           25,000,000           25,000,000    
Takeda License and Collaboration and Purchase Agreements                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Contract liability         600,000 0       600,000   0 600,000  
Research and development amount paid     $ 10,600,000                      
Collaborative agreement reduction in transaction price     14,300,000                      
Remaining transaction price     $ 3,700,000                      
Reduction in research and development expenses                       1,200,000 2,500,000  
Repayment liability         $ 3,700,000 $ 0       $ 3,700,000   $ 0 $ 3,700,000  
Arcturus Research Collaboration and License Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Research and development       $ 10,000,000